NIH × Interventional × Familial ependymoma × Clear all
NCT03210714 2026-03-19

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
20 enrolled 10 charts
NCT03233204 2024-12-11

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
6 enrolled 12 charts
NCT03526250 2024-11-01

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
23 enrolled 11 charts
NCT00019630 2024-03-04

Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
NCT00020150 2015-04-29

Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
NCT01088763 2014-11-05

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

National Cancer Institute (NCI)

Phase 1 Terminated
129 enrolled
NCT00002647 2013-09-20

Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors

National Cancer Institute (NCI)

Phase 1 Unknown
24 enrolled
NCT00349024 2013-09-20

Polyvinylpyrrolidone-Sodium Hyaluronate Gel in Reducing Pain From Oral Mucositis in Young Patients With Cancer

National Cancer Institute (NCI)

Phase NA Unknown
50 enrolled
NCT00994500 2013-07-02

Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
20 enrolled
NCT00091182 2013-06-05

Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment

National Cancer Institute (NCI)

Phase 2 Completed
180 enrolled
NCT00101270 2013-06-05

Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled
NCT00030108 2012-03-15

Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
30 enrolled
NCT00036959 2012-03-15

ABT-751 in Treating Young Patients With Refractory Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
90 enrolled
NCT00303940 2012-03-15

Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled